|
|
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements
|
|
|
T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
|
|
T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
|
|
T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock
|
|
|
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
|
|
|
T2 Biosystems Announces First Quarter 2024 Financial Results
|
|
|
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
|
|
|
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
|
|
|
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
|
|
|
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
|
